A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 134
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PR
Long Form : prolonged release
No. Year Title Co-occurring Abbreviation
2021 Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain. FDC, HCl, MMA, TKA
2021 Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release. CI, LBP, OA
2021 Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden. BSC, EDSS, ICER, kr, QALY, T25FW
2020 Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study. HF, HR, IR, SE, TEAEs
2020 Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). GH, IGF-1, ITT, SDS, SSA, TV
2020 Evaluation of the effect of naltrexone coadministration on the pharmacokinetics of oxycodone in a randomized phase 1 clinical trial
. PK
2020 Long-term effect of oxycodone/naloxone on the management of postoperative pain after hysterectomy: a randomized prospective study. BFI, NRS
2020 Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial. BFI, BPI-SF, LSM
2020 Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: post hoc analysis. QoL
10  2020 Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children. ---
11  2020 Tapentadol prolonged release for managing moderate to severe chronic neck pain with or without a neuropathic component. CI, NDI, QoL, ROM
12  2020 Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data. OA
13  2020 Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly: improvements in daily functioning and quality of life. OA
14  2019 Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulation in Indian patients with type 2 diabetes mellitus: a postmarketing observational study. ER, T2DM
15  2019 Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. ICF, MS, RCT, SMD
16  2019 Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study. LBP, NRI, NRS
17  2019 Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. PD, RBD
18  2019 Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study. CPRD, CR, HES, IRRs
19  2019 Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers. IR
20  2019 Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. C-CASA, IDS-SR, PAEs
21  2019 Tapentadol prolonged release and the long-term management of chronic musculoskeletal pain in the elderly - focus on anxiety, depression, cognitive status and life quality: the TaPE study. MOR, NRI, NRS
22  2019 Tapentadol prolonged release for pain control in a frail obese patient: a case report. ---
23  2019 Tapentadol prolonged release in association with analgesic radiofrequency for the treatment of chronic lumbar radicular pain: an observational, prospective study. MOR, NRI, NRS, RF
24  2019 Tapentadol prolonged release in fragile geriatric patients > 70 years with chronic severe musculoskeletal pain: an open-label, prospective, observational study. MOR, NRI, NRS
25  2018 Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. BBS, EDSS, MedDRA, MS, TUG
26  2018 Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. ---
27  2018 Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350. GI, OIC
28  2018 Effects of prolonged-release oxycodone/naloxone on pain control, bowel function and quality of life: A prospective observational study. OIBD, QoL
29  2018 Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials. CR, OA
30  2018 Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study. BDI-II, MFIS, MUSIQOL, T25FW
31  2018 Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis. 6MWT, PwMS, T25FW
32  2018 Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. MS
33  2018 Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study. OIC, OXN, QoL
34  2018 Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes. PAD
35  2017 A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease. PD
36  2017 A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR. BFI, CSBMs, OxyPR
37  2017 A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease. ---
38  2017 Comment on a paper by Dupoiron etal. "A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone- naloxone (up to 160/80mg daily) versus oxycodone PR". ---
39  2017 Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. CR
40  2017 Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability. MS, T25FW
41  2017 Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. 6MWT, PwMS, T25FW
42  2017 Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain. GI, OIC
43  2017 Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ---
44  2017 Prolonged-Release Oxycodone/Naloxone Improves Anal Sphincter Relaxation Compared to Oxycodone Plus Macrogol 3350. OIBD, PAC-SYM
45  2017 Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. CR, LS
46  2016 A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. AR, CNIs, ICER, IR, NMA, QALE, QALYs
47  2016 Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. ---
48  2016 Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy. HNC, NRS, PGIC
49  2016 Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. IR
50  2016 Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone. RLS
51  2016 Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations. BD, IR
52  2016 Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects. RLS
53  2016 Oxycodone with an opioid receptor antagonist: A review. ---
54  2016 Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment. CR, HRQoL, MID, RR
55  2016 Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. MS, PHYS, PSYCH
56  2016 Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400mg tablet formulations in normal male andfemale healthy subjects under fasting conditions
. ---
57  2016 Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy. ---
58  2016 Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data. WHO
59  2015 An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease. AEs, DB, OLE, PD, SAEs
60  2015 Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids. BFI, CI, EudraCT, MOR, OR, OXN, OXY, PROBE, WHO
61  2015 Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. NRS-3, RCI
62  2015 Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. MS, PCS
63  2015 Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain. ---
64  2015 Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome. RLS
65  2015 Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. BBS, TUG
66  2015 Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. DN4, MBD
67  2015 Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients. ---
68  2015 Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial. PAC-SYM
69  2014 A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. IR, SD
70  2014 Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial. ---
71  2014 Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands. HY, IR, PD
72  2014 Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study. ---
73  2014 Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study. ---
74  2014 Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists. ---
75  2014 Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis. DHI, MS
76  2014 Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. ---
77  2014 Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study]. BFI, FA, OIC, QoL
78  2014 Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations. ---
79  2014 Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. ---
80  2014 Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. CI, CR, OR, TEAEs
81  2014 The impact of new partial AUC parameters for evaluating the bioequivalence of prolonged-release formulations. BE, EMA, pAUC, PK
82  2014 [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d]. ---
83  2013 A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy. ---
84  2013 Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases. EDSS, FSS, MS, T25FW
85  2013 Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study. QoL
86  2013 Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. AEs, CI, Cmax, ECGs, HVD, IR, MRT
87  2013 Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. AEs, IR, NRS-3, WHO
88  2013 Oxycodone combined with opioid receptor antagonists: efficacy and safety. OXY
89  2013 Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists. WHO
90  2013 Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. IR, LOCF, NRS, WHO
91  2013 The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study. PD
92  2012 Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. BZD
93  2012 Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. QALYs
94  2012 Low absolute bioavailability of oral naloxone in healthy subjects. ---
95  2012 Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years. ---
96  2012 Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation. PGIC
97  2012 Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study. ---
98  2012 Tapentadol extended release: in adults with chronic pain. ER
99  2011 Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. BZD/Z
100  2011 Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. HF, PROBE